Drug Profile
Research programme: angiogenesis inhibitors - Catalyst Biosciences
Alternative Names: CB 18Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Catalyst Biosciences
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 18 Jul 2007 Preclinical development is ongoing